

Table 1. Demographic characteristics and serological results of patients infected with COVID-19 (n=888).

		Poor clinical outcome (PClinO)			Virological persistence (PVirO)	Good outcome (GO)	All
		Dead (PClinO3)	HCQ+AZ < 3 days (PClinO2)	HCQ+AZ ≥ 3 days (PClinO1)			
Number of sera		47	51	143	197	864	1302
Number of patients		29	25	53	100	681	888
Age (year)							
	Mean ±SD	78±13	59±12	68±14	44±13	42±14	45±17
	Median [Min-Max]	78 [28-97]	60 [39-80]	67 [31-90]	46 [18-72]	42 [14-81]	45 [14-97]
Male, n (%)		17 (59%)	17 (68%)	25 (47%)	43 (43%)	305 (45%)	408 (46%)
NEWS score, n (%)							
	0 – 4 (low)	1 (3%)	7 (28%)	24 (45%)	97 (97%)	649 (95%)	778 (88%)
	5 – 6 (medium)	3 (10%)	5 (20%)	13 (25%)	1 (1%)	20 (3%)	42 (5%)
	≥ 7 (high)	25 (86%)	13 (52%)	16 (30%)	2 (2%)	12 (2%)	68 (8%)
Median of sample collection in day [Min-Max]		8[0-27]	11[3-24]	11[2-35]	16[2-32]	16[3-38]	15[0-38]
Number of patients with multiples sera		10	13	43	70	163	299

Seroconversion, n (%)	1 (10%)	4 (31%)	18 (42%)	18 (26%)	45 (28%)	86 (29%)
Seroprevalence D0-D38*	8/29 (28%)	14/ 25 (56%)	26/53 (49%)	44/100 (44%)	241/681 (35%)	333/888 (37.5%)
Seroprevalence D0-D5*	1/11 (9%)	1/4 (25%)	0/12 (0%)	0/9 (0%)	0/24 (0%)	2/60 (3%)
Seroprevalence D6-D10*	2/13 (15%)	5/17 (29%)	6/31 (19%)	2/25 (8%)	11/111 (10%)	26/197 (13%)
Seroprevalence D11-D15*	2/6 (33%)	5/9 (56%)	14/32 (44%)	16/51 (31%)	60/267 (22%)	97/365 (27%)
Seroprevalence D16-D38*	5/5 (100%)	8/12 (67%)	12/17 (71%)	33/64 (52%)	184/421 (44%)	242/519 (47%)

* For the studied of seroprevalence, we considered only the sera with the higher IgG titer or with the higher IgM or IgA titer or only one negative sera when several sera were available for a same patients in the same studied period time.